Australia’s biggest week in biotech features the events of the year that the sector has known and  trusted for over 35 years, and attracts industry leaders, investors, researchers and regulatory and  government representatives. 

The two conferences will lift the profile of the Australian biotechnology industry, share new and  ground-breaking knowledge, connect companies, and create access to greater funding sources for  companies to develop world-class science into therapies, diagnostics and medical devices. 

AusBiotech 2021’s programme has been developed by industry for industry; online and on demand,  the five days are packed with more than 100 inspiring thought leaders from across 25 countries, in  almost 30 sessions. Delegates will be engaging, their way, as they pitch, partner, exchange ideas and remain engaged with our national and international biotech community.  

Keynote speakers bringing their expertise to AusBiotech 2021 include: 

• Dr Barney Graham, Former Deputy Director of the US NIAID Vaccine Research Center, one of the  ‘brains trust’ behind the design of Moderna’s COVID-19 vaccine, voted one of the world’s most  influential individuals of 2021 by Time Magazine, and a multi award-winning US immunologist,  virologist, and clinical trials physician; 
• Dr Paul Stoffels, Executive Vice President, Chief Scientific Officer, Johnson & Johnson; • Millis Oration keynote Professor Sharon Lewin, Director, Doherty Institute;  • Howard Sachs, Siemens Pharmaceutical Vertical Manager, Siemens Ltd; 
• Dr Niels Emmerich, Vice President and Global Head of Technology Search & Evaluation, AbbVie  Inc; 
• Professor Philip Hugenholtz, Co-Founder, Microba; and 
• Dr Victoria Gordon, Managing Director and CEO, QBiotics Group. 

The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2021 will recognise  and celebrate life science leaders who are championing the sector and the Australian community,  returning to the categories: Industry Leadership, Company of the Year and Emerging Company of  the Year. 

The ‘foundation stones’ for Australia’s regenerative medicine (RM) future will be completed with the  launch of three resources offering new knowledge and benchmarking, purpose, and a firm, unified  direction for the industry’s future. Join the Catalysing regenerative medicine in Australia panel 

discussion as industry leaders offer extensive insights and  

experience on the breadth of opportunity present in the  

Australian RM sector. 

AusBiotech’s Biotechnology Blueprint, the sector’s decadal  

framework, will be launched and sector-wide feedback sought. The strategy charts an ambitious  pathway to how the biotech industry can help solve problems and generate the long-term economic  growth and social capital that will be needed as we emerge from the current pandemic 

For fourth consecutive year, the national conference will feature the Early-Stage Investment Forum,  featuring quick-pitch presentations on early-stage technologies and projects. Offering each  presenter feedback which is critical for commercialisation, the expert investor panel will include  international big pharma representatives as well as corporate VCs and early-stage investors.  

Engaging capital with innovation, Australia Biotech Invest & Partnering 2021 is taking place on  Tuesday 26 October and remains the preeminent opportunity for companies to present their  technology and story to a network of potential international partners and investors. The full-day  programme features five keynote speakers and over 20 public and private companies, showcasing  the potential of life sciences. 

The Hon. Tim Pallas MP, Treasurer, Victorian Government, will join Lorraine Chiroiu, CEO,  AusBiotech to open the conference, before keynotes, company pitches, and Q&A sessions with  experienced investors take to the virtual stage.  

Australia Biotech Invest & Partnering 2021 keynote speakers include: 

• William F. McKeon, President & CEO, Texas Medical Center (USA); 
• Stacy Feld, Head, Johnson & Johnson Innovation, West North America, Australia & New Zealand  (USA); 
• Victor Windeyer, Portfolio Manager, Australian Unity Future of Healthcare Fund; • Kate Galpin, Business Development Manager, Listings, ASX Limited; and • David Weir, CEO and Co-Founder, Radium Capital. 

AusBiotech 2021 and Australia Biotech Invest & Partnering 2021 are proudly supported by their Host State Partner, the Victorian Government.  

Registrations remain open, and the programmes are available on demand throughout November.